GlassScriptPhysician profile
Michael S Holman
NPI 1598960619
$1,536.45
in general payments reported to CMS, 2019-2025
19 companies · $347 in 2025
The $347 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $88.43 · 2021: $102 · 2022: $293 · 2023: $245 · 2024: $280 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $285.55 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $195.20 | 2021-2025 | |
| Boston Scientific Corporation | $184.22 | 2023-2025 | Watchman Flx |
| Lexicon Pharmaceuticals, INC. | $174.39 | 2023-2024 | Inpefa |
| Pfizer INC. | $159.30 | 2019-2025 | |
| Amgen INC. | $102.02 | 2019-2022 | |
| Novo Nordisk INC | $83.07 | 2023-2025 | Wegovy, Ozempic |
| E.R. Squibb & Sons, L.L.C. | $62.34 | 2019-2023 | Eliquis |
| Abiomed | $47.24 | 2025 | |
| Abbott Laboratories | $41.89 | 2022 | |
| Abbvie INC. | $40.83 | 2020 | |
| Astellas Pharma US INC | $36.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.34 | 2024 | |
| Vital Connect, INC | $20.96 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.34 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $14.81 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.10 | 2022 | |
| Baxter Healthcare | $13.69 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Holman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.